Tiumbio Co Ltd. has described bromodomain-containing protein 4 (BD2 domain) (BRD4 BD2) inhibitors reported to be useful for the treatment of cancer, fibrosis, diabetes, metabolic syndrome, and renal and inflammatory disorders.